SUPPLEMENTARY METHODS

Data pre-processing
The raw data generated from the real-time PCR analysis was processed prior to statistical analysis to calculate accurate quantification cycle (C q ) values and quality check the data to eliminate failed measurements/missing values. The SDS files generated from the 7900HT Fast Real-Time PCR System were loaded 1 Authors contributed equally to the manuscript. 2 into the Sequence Detection Systems software distributed by Applied Biosystems. Clipped and Results files are exported for each SDS file. The Clipped-file contains the baseline-corrected normalized reporter signal ( Rn) values and the Results file contains the threshold and the C q values automatically assigned by the software. The threshold is adjusted to a value above the background and significantly below the plateau of an amplification plot. It must be placed within the linear region of the amplification curve, which represents the detectable log-linear range of the PCR. One threshold value is set for each assay, as described below. All sample-assay pairs in the data are subjected to the following procedure to set the C q values.
1. The intersection point between the given threshold and the Log 2 ( Rn) curve is found. 2. A linear model, Y = aX + b, is fitted to the closest Log 2 ( Rn) point below the intersection, along with two of the closest points above. 3. Another linear model is fitted to the closest Log 2 ( Rn) point above the intersection, along with two of the closest points below. 4. A QC test is performed on both models to see whether the model's slope is above a predefined value and the residual is below a predefined value. 5. If either one of the models passes the QC test criteria, the intersection point is set as the C q value. 6. The results are saved to a postscript file.
7. Each C q value along with the corresponding assay and sample name is stored for further statistical data analysis.
Component selection and decision boundary calculation
PLSR and LOOCV were used for model building and to estimate classification accuracy of the calibration set. Two components were finally selected as giving the optimum LOOCV efficacy (data not shown), with the ␤-coefficients for the final PLS model used for classification in the range from −3.46 to +3.32. From this LOOCV plot the results are skewed towards higher specificity than sensitivity, which could be compensated by changing the decision boundary (cut-off) from the default value of 0. The ROC for the final PLS model is shown in Fig. 2 . From the LOOCV classifications observed using the calibration samples, a possible decision boundary could be −0.077, which would provide an accuracy of 72.6%. However, from the LOOCV classifications, any value between −0.077 and −0.029 would give both sensitivity and specificity above 70%. Therefore after calculation of the midpoints, a plateau value of −0.04155 was chosen as the decision boundary in the final model. Classification values above −0.04155 are thus classified as AD, while values below −0.04155 are classified as cognitively healthy.
Diagnostic accuracy calculation and simulation model
The estimation of accuracy in the calibration and validation analyses were performed using clinical diagnosis as the 'gold standard', which has been assumed to be 100% correct. However, this assumption is overestimated, given that an accurate diagnosis in Alzheimer's disease (AD) may vary from 60% at GP clinics to over 90% at some specialized clinics [1] [2] [3] . Using the clinical diagnosis as reference will therefore underestimate the sensitivity and specificity of the test under evaluation. Therefore, a simulation model was prepared to determine the expected accuracy based on the approach proposed by Albert [4] that focuses on joint modeling of multiple tests, but also includes the test-specific estimators. From the article:
where i is the index for subject and j the index for the test, while P(T i |d i ) is estimated from a previous study. In both the joint modeling and test-specific modeling, this approach simplifies when P(
According to Albert the sensitivity and specificity for the j'th test can be estimated by maximizing the loglikelihood of (1) separately for each test. In our study there is only one reference test, the clinical diagnosis. Thus for our analysis the 96-gene assay test is Y, the clinical diagnosis is T and d is the prevalence. If we assume that Y and T are independent, the equations can be written as:
From previous studies we have an estimate of P(Y i ,T i ) (the overall accuracy) and have made some assumptions regarding the clinically accuracy. If we assume the sensitivity and specificity are the same in the clinical setting, then P(T i |d i = l) will have the same value for both l's in the above equation. If the assumed sensitivity and specificity are the same, the prevalence, P(d i = l), for this population will be 50%.
With an overall accuracy of 0.726, the assumed sensitivity and specificity of clinical diagnosis of 0.80 and a prevalence of 0.50, then equation (2) can be solved for P(Y i |d i = 1) and P(Y i |d i = 0). As these are the only functions of the equation, the maximum likelihood is calculated as normal. The sum of these must equal 1.815, giving possible combinations ranging from 0.82 to 1.0 for each of the two probabilities. However, the overall accuracy will be the same for all these combinations, 0.91.
In order to have an overview of the possible impact of an imperfect gold standard some data simulations have been performed. The following method/algorithm was used:
1. One hundred samples were set to have true AD and 100 as true healthy. 2. Each of these 200 samples was diagnosed as AD or healthy, with a probability of 80% being according to true diagnosis (simulation of the clinical diagnosis).
Each of the original 200 samples was diagnosed
as AD or healthy, with different probabilities (from 60 to 100%) of being in agreement with the true diagnosis (simulation of the 96-gene assay or similar test). 4. The results from 3 were then evaluated using 2 as the gold standard, and the sensitivity according to clinical diagnosis was calculated. 5.
Step 1-4 was repeated 100,000 times for each probability used in 3.
The results from the simulations, at an assumed clinical accuracy of 80% are shown below: From this table it can be seen that the mean value and the medians are very similar, and therefore it can be concluded that the underlying distributions are symmetric. Minimum and maximum values should be interpreted in light of 100,000 simulations for each level of accuracy and are therefore expected to be either very low or very high.
Considering the mean values, a true accuracy of 85% would be expected to give an observed accuracy of 71% when compared with the clinical diagnosis, while 100% accuracy would be expected give an observed accuracy of 80%. In the calibration and validation stud-Supplementary Therefore, comparing the results of the 96-gene assay test with an imperfect gold standard will most likely underestimate the accuracy. Assuming an accuracy of 80% for the clinical diagnosis compared with the truth, the above calculations and simulations suggest that the accuracy of the 96-gene assay test is in the range 85%-90% when compared with the underlying truth.
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